TG Therapeutics beats Q3 2026 estimates on BRIUMVI momentum
As seen on the 24/7 Wall St. homepage on November 9, 2026.
TG Therapeutics is on track for a roughly $1 billion full-year global revenue target less than four years after launching BRIUMVI. Pivotal Phase 3 data on a subcutaneous version lands around year-end.
Continue ReadingShow less
TG Therapeutics reported Q3 2026 earnings per share of $0.35 on a GAAP basis, beating the consensus estimate of $0.26. Revenue of $259.9 million also came in above expectations.
The growth engine was BRIUMVI, the company's anti-CD20 therapy for relapsing multiple sclerosis. U.S. net product revenue from BRIUMVI reached $232.6 million in the quarter, with license, milestone, royalty and other revenue tied largely to the Neuraxpharm partnership covering ex-U.S. sales adding the rest.
Off the strength of that quarter, management raised its full-year 2026 total global revenue target to approximately $1 billion and tightened BRIUMVI U.S. net product revenue guidance upward. The company also repurchased about $100 million of its own shares during the quarter.
Sponsored
The next major catalyst investors are watching is topline Phase 3 data for a subcutaneous formulation of BRIUMVI, expected at year-end 2026 or in early 2027. A subcutaneous version would allow self-administration and quarterly dosing, broadening the drug's reach beyond its current intravenous patient base. If Phase 3 results support approval, management has flagged a subcutaneous launch in 2028.
Net income of $55.5 million was down sharply from a year ago, when the comparison was inflated by a roughly $365 million non-recurring tax benefit. Operating income, which strips out that distortion, rose 192.5% year over year, a cleaner read on the underlying business trajectory.
Mentioned: TGTX